Currently, there are 588.60M common shares owned by the public and among those 576.41M shares have been available to trade.
The company’s stock has a 5-day price change of 1.28% and -3.64% over the past three months. EW shares are trading -3.77% year to date (YTD), with the 12-month market performance down to -24.76% lower. It has a 12-month low price of $58.93 and touched a high of $96.12 over the same period. EW has an average intraday trading volume of 4.50 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.96%, -0.16%, and -2.17% respectively.
Institutional ownership of Edwards Lifesciences Corp (NYSE: EW) shares accounts for 87.16% of the company’s 588.60M shares outstanding.
It has a market capitalization of $41.88B and a beta (3y monthly) value of 1.18. The stock’s trailing 12-month PE ratio is 29.90, while the earnings-per-share (ttm) stands at $2.38. The company has a PEG of 3.59 and a Quick Ratio of 3.45 with the debt-to-equity ratio at 0.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.04% over the week and 2.46% over the month.
Analysts forecast that Edwards Lifesciences Corp (EW) will achieve an EPS of 0.6 for the current quarter, 0.62 for the next quarter and 2.74 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.58 while analysts give the company a high EPS estimate of 0.58. Comparatively, EPS for the current quarter was 0.66 a year ago. Earnings per share for the fiscal year are expected to increase by 0.95%, and 12.09% over the next financial year. EPS should grow at an annualized rate of 8.32% over the next five years, compared to 7.29% over the past 5-year period.
Looking at the support for the EW, a number of firms have released research notes about the stock. Stifel stated their Buy rating for the stock in a research note on January 30, 2025, with the firm’s price target at $75-$90. Wolfe Research coverage for the Edwards Lifesciences Corp (EW) stock in a research note released on January 16, 2025 offered a Underperform rating with a price target of $60. BofA Securities was of a view on December 16, 2024 that the stock is Buy, while Morgan Stanley gave the stock Equal-Weight rating on October 11, 2024, issuing a price target of $70. Jefferies on their part issued Hold rating on September 18, 2024.
